Abstract: Provided herein are water-soluble polymer conjugates and polymer-based compositions of antimicrobial agents. Also provided are methods for synthesizing and administering such conjugates and compositions.
Abstract: This invention deals with a carboxyl-bearing, amphiphilic, solid copolyester stent coating composition for multifaceted prevention of vascular restenosis through a plurality of physicopharmacological modes. The composition includes one or more bioactive compounds and a copolymerization product of polyalkylene glycol, end-grafted with one or more cyclic monomer and treated further to introduce carboxyl-bearing end- or side-groups. The invention also deals with bioactive agents in an ionically conjugated form. The present coating may be applied to a metallic or an absorbable polymeric stent for use in preventing vascular restenosis.
Abstract: The present invention provides polymer micelles with cross-linked ionic cores as delivery vehicles for therapeutics, diagnostics, nucleic acids, proteins, small molecules and the like. The present invention provides additionally methods of synthesis and uses for such micelles.
Type:
Grant
Filed:
January 21, 2008
Date of Patent:
April 9, 2013
Assignee:
Board of Regents of the University of Nebraska
Inventors:
Tatiana K. Bronich, Alexander V. Kabanov
Abstract: Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH2 are biologically active compounds; each X is independently selected from —CH2COO— (glycolic acid moiety), —CH(CH3)COO— (lactic acid moiety), —CH2CH2OCH2COO— (dioxanone moiety), —CH2CH2CH2CH2CH2COO— (caprolactone moiety), —(CH2)yCOO—, where y is 2-4 or 6-24 and —(CH2CH2O)zCH2COO—, where z is 2-24; each Y is independently selected from —COCH2O— (glycolic ester moiety), —COCH(CH3)O— (lactic ester moiety), —COCH2OCH2CH2O— (dioxanone ester moiety), —COCH2CH2CH2CH2CH2O— (caprolactone ester moiety), —CO(CH2)mO—, where m is 2-4 or 6-24 and —COCH2O(CH2CH2O)n— where n is between 2-24; R? is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.
Abstract: Onychomycosis present in a nail is treated by debridement such as grinding a portion of the nail, which includes an infected portion and thereafter applying a composition containing alkyl cyanoacrylate to the debrided surface which cures to a hard layer. The hard layer can be successively ground and coated with successive layers of alkyl cycanoacrylate.
Abstract: A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed by using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having complexing sites, and cross-linking monomers, which are copolymerized using a suitable initiator. The complexing sites of the recognitive polymeric hydrogel that is formed preferably mimics receptor sites of a target biological tissue, biological recognition, or biological mechanism of action. The system in accordance with an embodiment of the intention is a contact lens for delivering a drug through contact with an eye.
Abstract: The invention provides compositions comprising a polyamidoamine (PAA) polymer comprising a pendant disulphide, sulphydryl, or activated sulphydryl moiety, and methods for their manufacture. The invention extends to the use of such polyamidoamine polymers to form cross-linked compositions, and hydrogels comprising the same, and the use of such compositions in various biological and non-biological applications, such as the delivery of biomolecules to target sites, and for tracking fluid flows. The invention also provides carrier particles, which may be used to deliver biomolecules, and to methods of treatment. The invention also provides a fluid tracking system for monitoring fluid flow.
Type:
Grant
Filed:
September 14, 2007
Date of Patent:
March 26, 2013
Assignees:
The University of Nottingham, The University of Milan
Inventors:
Martin Garnett, Paolo Ferruti, Elisabetta Ranucci
Abstract: The invention relates to a material consisting of an aqueous dispersion of PEG-coated nanoparticles of maghemite. The process for preparing said material consists in polymerizing ethylene oxide in the presence of nanoparticles of maghemite in an aqueous dispersion. The polymerization is initiated using reactive groups which are capable of initiating the polymerization of ethylene oxide without the addition of a catalyst, and which are attached to the nanoparticles of maghemite by means of a coupling agent comprising an alkoxysilyl group and one or more of said reactive groups. Applications: contrast agent for MRI.
Type:
Grant
Filed:
February 7, 2007
Date of Patent:
March 19, 2013
Assignees:
Centre National de la Recherche Scientifique (C.N.R.S.), Universite de Haute Alsace
Inventors:
Christelle Delaite, Christophe Flesch, Philippe Dumas
Abstract: A method for producing spherical ferrite nanoparticles includes the steps of: preparing a first aqueous solution containing a disaccharide, an alkaline, an oxidation agent, seed particles and divalent iron ions; and conducting particle growth in the first aqueous solution to produce the spherical ferrite nanoparticles.
Type:
Grant
Filed:
December 28, 2007
Date of Patent:
March 19, 2013
Assignees:
Tokyo Institute of Technology, Tamagawa Seiki Kabushiki Kaisha
Abstract: Biodegradable polymeric compositions that are liquids or pastes at temperatures below 37° C. are described. Immersion of the compositions in aqueous medium, such as body fluids, increases the viscosity of the composition resulting in the formation of a semisolid material. The polymeric material is a hydroxyalkanoic acid polyester derived from the copolymerization of at least one unsaturated hydroxy fatty acid copolymerized with hydroxyalkanoic acids of 2-6 carbons.
Abstract: Spherical ferrite nanoparticles produced by a method that includes the steps of: preparing a first aqueous solution containing a disaccharide, an alkaline, an oxidation agent, seed particles and divalent iron ions; and conducting particle growth in the first aqueous solution to produce the spherical ferrite nanoparticles.
Type:
Grant
Filed:
April 2, 2012
Date of Patent:
March 12, 2013
Assignees:
Tokyo Institute of Technology, Tamagawa Seiki Kabushiki Kaisha
Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
Type:
Grant
Filed:
March 23, 2012
Date of Patent:
March 12, 2013
Assignee:
Jagotec AG
Inventors:
Guy Vergnault, Pascal Grenier, Christophe Dragan
Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
Type:
Grant
Filed:
December 17, 2010
Date of Patent:
March 12, 2013
Assignee:
Supernus Pharmaceuticals, Inc.
Inventors:
Rong-Kun Chang, Arash Raoufinia, Niraj Shah
Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
Type:
Grant
Filed:
November 30, 2007
Date of Patent:
March 12, 2013
Assignee:
Nektar Therapeutics
Inventors:
Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
Type:
Grant
Filed:
December 17, 2010
Date of Patent:
March 12, 2013
Assignee:
Supernus Pharmaceuticals, Inc.
Inventors:
Rong-Kun Chang, Arash Raoufinia, Niraj Shah
Abstract: A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having complexing sites, and cross-linking monomers, which are copolymerized using a suitable initiator. The complexing sites of the recognitive polymeric hydrogel that is formed mimic receptor sites of a target biological tissue, biological recognition, or biological mechanism of action. A system in accordance with some embodiments is a contact lens for delivering a drug through contact with an eye. In some embodiments, the drug is an anti-microbial, such as an anti-fungal agent for treatment of large animals. In some embodiments, a comfort molecule hyaluronic acid (HA) is delivered.
Abstract: Disclosed is an anti-cancer medicine comprising a chain end functionalized polymer, a contrast material such as iron oxide and a chemotherapeutic agent such as doxorubicin or pharmaceutically acceptable salts thereof. The anti-cancer medicine performs diagnosis and treatment of cancer at the same time, remarkably reduces a cardiotoxic side effect of the doxorubicin and has an excellent targeting function to the cancer part to considerably increase the anti-cancer effect. At the same time, the anti-cancer medicine is provided as MRI contrast medium which can diagnose the cancer and monitor a progress of the disease. In particular, the anti-cancer medicine is disclosed which is superior to the diagnosis and treatment of the solid cancer and can effectively perform the diagnosis and treatment of the metastatic cancer as well as the primary cancer at the same time.
Abstract: Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury.
Type:
Grant
Filed:
April 25, 2007
Date of Patent:
February 19, 2013
Assignees:
Children's Medical Center Corporation, Massachusetts Institute of Technology
Abstract: The invention concerns a rapidly disintegrating tablet similar to those designed to disintegrate in the mouth on contact with saliva in less than 30 seconds, forming an easy-to-swallow suspension, and based on an active substance in the form of coated microcrystals or microgranules and a mixture of excipients including at least a disintegrating agent, a soluble agent and a lubricating agent. The invention is characterized in that the lubricating agent is in powder form and is distributed at least for the greater part on the tablet surface and its friability, measured as specified in the French Pharmacopoeia (10th Edition, V.5.1—Friability of Tablets, January 1993), is less than 1%, and preferably less than 0.
Type:
Grant
Filed:
February 29, 2000
Date of Patent:
February 19, 2013
Assignee:
Ethypharm
Inventors:
Laurent Di Costanzo, Edouard André Gendrot, Mathieu Ernest Jean-Baptiste Di Costanzo, Charles André Chauveau
Abstract: UI3(1,4-dioxane)1.5 and UI4(1,4-dioxane)2, were synthesized in high yield by reacting turnings of elemental uranium with iodine dissolved in 1,4-dioxane under mild conditions. These molecular compounds of uranium are thermally stable and excellent precursor materials for synthesizing other molecular compounds of uranium including alkoxide, amide, organometallic, and halide compounds.
Type:
Grant
Filed:
January 19, 2012
Date of Patent:
February 19, 2013
Assignee:
Los Alamos National Security, LLC
Inventors:
Jaqueline L. Kiplinger, Marisa J. Monreal, Robert K. Thomson, Thibault Cantat, Nicholas E. Travia